Elizabeth Shpall, MD
Medical Oncology · Houston, TXNPI 1326139098
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Gilead at 53.3% of the total. Reporting peaked in 2024 at $36,807 and has fallen 86.2% since, to $5,076 in 2025.
Across 87 payments — averaging $671.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$31K
- National Marrow Donor Program$17K
- Novartis$10K
- Jazz Pharmaceuticals Inc.$682
- Partner Therapeutics, Inc.$98
- AstraZeneca$83
- plus $147 from 3 others
Across 1 payment — averaging $392,423 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$392K
What the payments were for
- Consulting fees$21,61537%
- Travel & lodging$31,56454%
- Food & beverage$4,9909%
- Gifts$1300%
- Entertainment$1550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 17 | $31,158 |
| National Marrow Donor Program | 54 | $16,726 |
| Novartis | 6 | $9,559 |
| Jazz Pharmaceuticals Inc. | 5 | $682 |
| Partner Therapeutics, Inc. | 1 | $98 |
| AstraZeneca | 1 | $83 |
| Bristol Myers Squibb | 1 | $60 |
| Genetix Biotherapeutics Inc | 1 | $45 |
| Vertex | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,453 in reported general payments places this provider in the 80th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 12 | $268 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.